DUBLIN–(BUSINESS WIRE)–The “Global
Neurodegenerative Disease Market Analysis & Outlook 2019-2024”
report has been added to ResearchAndMarkets.com’s
offering.
The major factors for the growth of the neurodegenerative disease market
include the rising prevalence of neurological disorders, increasing
public awareness, and strong product pipeline for neurodegenerative
disease treatment.
Key Market Trends
Parkinson’s Disease Segment by Indication Type is Expected to Be the
Fastest Growing Segment
The initial symptoms of Parkinson’s disease include shaking, rigidity,
uneasiness in walking, and slowness. Anxiety and depression are very
common in patients suffering from Parkinson’s disease.
Anti-Parkinson drugs, such as Levodopa and Carbidopa, are the most
commonly administered drugs, along with dopamine agonists. Ropinirole,
Pramipexole, and Rotigotine are some common dopamine agonists prescribed
for the disease. Selegiline and Rasagiline are the drugs that conserve
dopamine and prevent degradation. COMT inhibitors are also administered
to prevent the degradation of dopamine.
According to the Parkinson’s Disease Foundation, nearly 10 million
people worldwide are living with Parkinson’s disease. The risk of
Parkinson’s disease increases with age. The growing aging population,
especially in North America and Europe, is the primary factor propelling
the growth of the market. The increasing awareness and incidences of the
disease are boosting the market growth.
According to the Parkinson’s Disease Foundation, medication cost for a
patient with the disease is on an average USD 2,500 a year, and
therapeutic surgery costs nearly USD 100,000 per person. In 2017, North
America accounted for the largest market, followed by Europe and
Asia-Pacific.
North America is Expected to Dominate the Market
North America is the most significant region in Parkinson’s drugs
market. As many as one million Americans live with Parkinson’s disease
(PD), which is more than the combined number of people diagnosed with
multiple sclerosis, muscular dystrophy, and Lou Gehrig’s disease.
According to Parkinson’s news, 2018, approximately 1.2 million people in
the United States are predicted to have Parkinson’s disease by 2030. It
is the second-most common neurodegenerative disorder in the United
States. Also, there are thousands of patients who go undetected. As the
US population continues to age, the number of people living with
Parkinson disease (PD) continues to grow, and it is expected to double
between 2010 and 2040.
Recently, the Food and Drug Administration (FDA) approved safinamide
(Xadago) tablets as an add-on treatment to levodopa/carbidopa for
patients with PD, who are experiencing “off” episodes. FDA approved the
drug in March 2017. On the other hand, patients are adopting the
generics due to the low cost, and are further expected to restrain the
patented drugs. Hence, this generic competition between the new entrants
is expected to show a steady growth rate, during the forecast period.
Competitive Landscape
The market studied is a consolidated, owing to the presence of a few
major market players. Some of the market players are AbbVie, Amneal
Pharmaceuticals, Boehringer Ingelheim Group, F. Hoffmann-La Roche,
GlaxoSmithKline, Merck & Co, Pfizer, Teva Pharmaceutical, and UCB.
Key Topics Covered
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Neurological Disorders
4.2.2 Increasing Public Awareness
4.2.3 Strong Product Pipeline for Neurodegenerative Disease Treatment
4.3 Market Restraints
4.3.1 Patent Expiry of Neurodegenerative Disease Treatment Products
4.3.2 Stringent Regulatory Guidelines
4.4 Porter’s Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Indication Type
5.1.1 Parkinson’s Disease
5.1.2 Amyotrophic Lateral Sclerosis
5.1.3 Alzheimer’s Disease
5.1.4 Huntington Disease
5.1.5 Other Indication Types
5.2 By Drug Type
5.2.1 N-methyl-D-aspartate Receptor
5.2.2 Selective Serotonin Reuptake Inhibitor
5.2.3 Dopamine Inhibitors
5.2.4 Other Drug Types
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Amneal Pharmaceuticals Inc.
6.1.3 Boehringer Ingelheim International GmbH
6.1.4 F. Hoffmann-La Roche Ltd.
6.1.5 GlaxoSmithKline PLC
6.1.6 Merck & Co. Inc.
6.1.7 Pfizer Inc.
6.1.8 Teva Pharmaceutical
6.1.9 UCB S.A.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/ix70x
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs